3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
55
Carcinoma, Hepatocellular
54
Lung Neoplasms
32
Small Cell Lung Carcinoma
28
Neoplasms
25
Breast Neoplasms
20
Colorectal Neoplasms
18
Melanoma
15
Urinary Bladder Neoplasms
13
Triple Negative Breast Neoplasms
13
Carcinoma, Transitional Cell
13
Neoplasm Metastasis
12
Carcinoma, Renal Cell
12
Squamous Cell Carcinoma of Head and Neck
10
Prostatic Neoplasms
9
Uterine Cervical Neoplasms
8
Glioblastoma
8
Stomach Neoplasms
7
Endometrial Neoplasms
7
Ovarian Neoplasms
6
Head and Neck Neoplasms
6
Sarcoma
5
Pancreatic Neoplasms
5
Carcinoma, Neuroendocrine
5
Carcinoma, Merkel Cell
5
Liver Neoplasms
4
Kidney Neoplasms
4
Extensive Stage Lung Small Cell Carcinoma
4
Carcinoma
4
Brain Neoplasms
4
Interventions
Docetaxel
2
Cisplatin
2
130-nm albumin-bound paclitaxel
2
taxane
1
pembrolizumab
1
liposomal doxorubicin
1
durvalumab
1
cemiplimab
1
atezolizumab
1
Pemetrexed
1
Paclitaxel
1
Nivolumab
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Biosimilar Pharmaceuticals
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vaccinia
×
atezolizumab
×
1 year
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled